CAPTRUST Financial Advisors
MNPR icon

CAPTRUST Financial Advisors’s Monopar Therapeutics MNPR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34
Closed – – 3261
2022
Q2 		$0 Buy
+34
New +$385 ﹤0.01% 5058
2022
Q1 		– Sell
-34
Closed -$1K – 5049
2021
Q4 		$1K Hold
34
– – ﹤0.01% 4599
2021
Q3 		$1K Hold
34
– – ﹤0.01% 4451
2021
Q2 		$1K Hold
34
– – ﹤0.01% 4356
2021
Q1 		$1K Hold
34
– – ﹤0.01% 4210
2020
Q4 		$1K Buy
+34
New +$878 ﹤0.01% 3278
2020
Q3 		– Sell
-34
Closed -$1K – 3162
2020
Q2 		$1K Buy
+34
New +$1.31K ﹤0.01% 2725

Other funds holding MNPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CAPTRUST Financial Advisors's MNPR Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Monopar Therapeutics (MNPR) in Q3 2022, closing a stake of 34 shares.

CAPTRUST Financial Advisors first reported a position in MNPR in Q2 2020 and held it in 7 quarters. The position peaked at $1K in Q4 2021. 10 funds tracked by Wall St. Rank hold MNPR as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Monopar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 34 Monopar Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Monopar Therapeutics in Q2 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Monopar Therapeutics position peaked at $1K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.